Genomic Health Preps for December Launch of DCIS Test as Q3 Revenues Rise 12 Percent | GenomeWeb

By Bernadette Toner

Genomic Health is planning to launch its Oncotype DX test for ductal carcinoma in situ in December, following the San Antonio Breast Cancer Symposium, where it will present the results of its validation study for the test, company officials said this week.

The company also plans to launch before the end of the year an immunohistochemistry test for mismatch repair protein status that will complement its Oncotype DX colon cancer test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.